eGenesis is a biotechnology company dedicated to advancing the field of regenerative medicine through genome editing technology. The company aims to provide safe and effective human transplantable cells, tissues, and organs, addressing the critical shortage of available transplants. eGenesis is involved in pioneering research and development, particularly focused on utilizing genetically-engineered pigs as a source for human-compatible organs. The organization emphasizes a collaborative environment that prioritizes innovation, ethical practices, and regulatory compliance to ensure the highest standards of animal welfare and safety. As a forward-thinking company, eGenesis is positioned at the intersection of cutting-edge science and real-world application, making significant strides towards transformative solutions in transplantation medicine.